NCT00434733View on ClinicalTrials.gov

Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects

PHASE3CompletedINTERVENTIONAL

Enrollment

4,400

Participants

Timeline

Start Date

January 31, 2007

Conditions

Influenza

Interventions

BIOLOGICAL

Pandemic influenza vaccine

Trial Locations (1)

30-969

Centrum Badań Farmakologii Klinicznej monipol, Krakow

Sponsors

Lead Sponsor

Collaborators (1)

Novartis Vaccines

All Listed Sponsors

collaborator

Novartis Vaccines

INDUSTRY

lead

Novartis

INDUSTRY

NCT00434733 - Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects | Biotech Hunter | Biotech Hunter